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Abstract:  Chiropractors and other healthcare practitioners
primarily concerned with the treatment and diagnosis of
disorders of the musculoskeletal system are often presented
with patients complaining of extremity joint pain.  The
signs and symptoms of Ross River and Barmah Forrest
arbovirus infections can often be confused with a number
of other conditions including local joint infection,
rheumatoid diseases and other systemic diseases causing
arthralgic or myalgic symptoms.  This paper presents a
review of the often debilitating conditions caused by the
Ross River and Barmah Forest arboviruses.  These
increasingly common viruses can produce symptoms of
arthralgia, fever, myalgia, rash and headache.  A systematic
review of the structure of these viruses, their epidemiology,
clinical manifestations, treatment and prevention are
presented.
Key Indexing Terms:  Ross River arbovirus, Barmah
Forrest arbovirus, arthralgia, myalgia, fever,
musculoskeletal pain, joint pain.
INTRODUCTION
Four arboviruses (arthropod-borne viruses), that are
members of the alphavirus genus of the family Togaviridae,
have to date been isolated in Australia.  They are Ross
River virus (RRV), Barmah Forest virus (BFV), Sindbis
virus (SIN) and Getah virus (GET).1,2  All four viruses
have been shown to infect humans, and all but GET are
pathogenic to man.  GET has only been reported to cause
disease in horses in Japan.2  SIN is the most widely spread
arbovirus, extending from northern Europe to southern
Africa and right through to Asia and Australia.  Birds are
the major vertebrate hosts, although SIN can infect and
cause fever and rash in humans.1  RRV and BFV are two
of the most important arboviruses in Australia, especially
in terms of human disease.  Both, although being related
but distinct viruses, cause similar symptomatology, with
epidemic polyarthritis (EPA) being the most common and
significant symptom.  RRV is responsible for about 90%
of EPA cases, with BFV being responsible for the remaining
10%.3,4  Consequently, this paper will discuss principally
RRV and BFV and their effects.
The symptoms of RRV infection were first described by J
R Nimmo 5, “.... there has occurred a number of cases of
a disease which I cannot nail down as any known epidemic,
nor cast into the practitioner’s “dust-bin” of diagnosis and
name “influenza”.  ....There are three main symptoms:
pain, skin eruption and general manifestations.” (p549).
The virus was first isolated in 1963 from mosquitoes by
Doherty et al 6, then retrieved from an EPA patient in 1981
by Aaskov et al.7  Three genotypes of RRV have been
defined, with each predominating in a different
geographical region of Australia.  95% nucleotide sequence
homology still exists between the three genotypes, but the
significance of the differences with regards to
pathogenicity, remains to be determined.4,8
BFV was first isolated from mosquitoes in the summer of
1974 from the Barmah Forest in northern Victoria.9  It was
first suggested to be pathogenic to man in 1988 by Boughton
et al,10 who described three patients with symptoms
consistent with arboviral infection, and with retrospective
testing of sera, pointed to BFV as the likely causative
agent.  BFV is an atypical alphavirus, and as such, has been
classified as the sole known member of the seventh
alphavirus serocomplex.9  BFV is only found on mainland
Australia.4
STRUCTURE
The RRV genome consists of single-stranded positive
sense RNA that is approximately 11.8 kb long.  The
genome produces four nonstructural proteins (nsP1-4)
and five structural proteins (capsid, 6K and E1-3) with the
capsid protein forming a shell that protects the viral
genome.11  E2 contains three neutralisation epitopes (a, b1
and b2), and all three are able to elicit neutralisation
antibodies in the host.12
BFV genomic RNA is 11,488 nucleotides in length,
excluding the poly(A) tail.  It has two open reading frames,
one coding for four nonstructural proteins, the other
coding for five structural proteins.  Note that these are
designated the same as for RRV, however they differ at the
molecular level.9
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There are enough similarities between the RRV and the
BFV genomes to place them in the same genus, although
there are some significant differences.  For example, the
E2 protein of BFV has no N-linked glycosylation sites,
whereas all other sequenced alphaviruses do.  A 388nt
sequence in E2 only displays 49.5% homology with RRV,
and BFV shows little serological cross-reaction with other
alphaviruses.  The differences are significant enough to
entitle BFV to occupy its own serological classification.2,9
EPIDEMIOLOGY
Sporadic cases of RRV disease appear in all states of
Australia throughout the year, however significant disease
incidence tends to occur in epidemics.13  Several epidemics
have been reported, the first of course was by Nimmo.5  In
1979/1980, RRV was exported to several South Pacific
islands from the east coast of Australia, resulting in one of
the largest epidemics recorded.  The explosive nature of
the epidemic (greater than 50,000 clinical cases), suggested
the appearance of a new disease not endemic to these
areas.  Together with all isolates being a single RRV
variant resembling the genotype found on the east coast of
Australia, reasonable evidence supports the notion that
RRV was exported there.  RRV has not been detected in
these islands since the epidemic of 1979/1980.2,14
Hawkes et al15 described an outbreak of EPA in NSW in
the summer of 1983/1984 with at least 1196 confirmed
cases.  This was the largest outbreak of EPA since 1956,
when there was an estimated 1000-2000 cases in Mildura
alone.  Almost equal numbers of males and females were
affected, with the highest frequency of clinical infection
occurring in the 30 to 39 age group.  In this outbreak, there
was a high proportion of clinical to subclinical infections
(257:340 estimated for Griffith), although previous studies
have suggested a much lower ratio normally exists (1:50).
Hawkes et al15 suggested the variations in ratios may be
due to variations in virus virulence, or to differences in the
passage of the virus: human-vector-human as opposed to
animal-vector-human.  At present, one can only speculate.
Other epidemics that have occurred in recent history are
the 1988/1989 outbreak of RRV disease in the south-west
of Western Australia,16 and the RRV outbreak in the north
of the Northern Territory in 1990/1991.17
The epidemiological picture for BFV disease is somewhat
less clear, with the data collected thus far supporting no
firm conclusions.  Much smaller epidemics occur, either
coinciding with RRV disease, or in the distinct absence of
RRV activity.16  Phillips et al18 report 29 cases of clinical
BFV infection between July 1988 and March 1989 from
Queensland, NSW and Victoria (21 of them from
Queensland).  They also provide evidence of extensive
subclinical infection with a serological study suggesting
that 0.23% of the Queensland population is infected with
BFV each year.  The same study suggested that 0.59% of
the Queensland population is infected with RRV annually.
Another ‘epidemic’ of 22 cases of BFV disease was
reported from the south-west of Western Australia from
August 1992 to March 1994.16  There was no conclusive
evidence of BFV activity in this region of WA prior to
1992, with no isolations during 6 years of mosquito
surveillance and no diagnosed human cases.  This epidemic
of BFV occurred in the absence of significant RRV
activity, suggesting as yet undescribed subtle differences
in the ecology of BFV and RRV.  Yet another BFV disease
outbreak occurred along the south coast of NSW in 1995.4
Several retrospective serological studies have been
conducted in order to estimate the degree of subclinical
infection with alphaviruses.  Boughton et al1 tested 16,842
samples of sera collected during 1981 and 1982 from all
regions of NSW for the prevalence of alphavirus antibodies.
Figures varied from age group to age group and from
region to region, however for the entire population tested,
16.9% of males and 11.1% of females had antibodies to
alphaviruses. RRV antibodies were found in 2149 samples,
SIN antibodies in 145 samples and an unknown alphavirus
was found to have infected 152 samples (NB, BFV was not
being tested for at this time).  No anti-GET antibodies
were detected.  The Western plains region demonstrated
the highest degree of seroprevalence, with 31.5% of under
20 year olds and 50.5% of over 40 year olds having anti-
alphavirus antibodies.  The township of Bourke had an
overall seropositivity rate of 66%.  Hawkes et al15 reported
that the incidence of RRV seropositivity in NSW has
increased almost across the board relative to the study
conducted in 1981.  Seroprevalence at the time of this
study ranged from 72% in Bourke to 25% in Cohuna.
Hawkes et al19 conducted a serological survey to determine
the prevalence of  BFV infection in NSW.  Anti-BFV
antibodies were found to be widespread in humans from
all regions of NSW, with seropositivity rates significantly
higher in males (2.5%) than in females (1.4%).  The
highest concentration of infections was recorded from the
north coast of NSW, (RRV seroprevalence in NSW is
highest in the Western plains region).  Overall, antibody
prevalence rates for BFV were low compared to other
alphaviruses, especially RRV.
The numbers of clinical infections are increasing every
year, with 1039 cases of RRV disease throughout Australia
in 1980/198118,20 to 2602 cases of RRV disease and 756
cases of BFV disease in Australia in 1995.13  However,
Wolstenholme14 predicts in the long term, our grandchildren
will be infected when they are very young and numbers of
clinical cases will decrease.
In 1989 Kay and Aaskov proposed marsupials and
especially macropods (wallabies, kangaroos etc), were
the main vertebrate hosts in which RRV was normally
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maintained.  Infections however, have been observed in a
wide range of both domestic and feral animals.4  Most
authors tend to concur with this proposal although
Wolstenholme14 contests this theory.  He states that droughts
and winter animal populations are too small to sustain the
virus life cycle, and hypothesizes that the virus is passed
down generations of mosquitoes through transovarial
transmissions.  He concedes however, that animal and
human infections are probably necessary to increase the
number of infected mosquitoes prior to an outbreak.
A study by Lindsay et al16 determined that in arid regions
of Western Australia, RRV may persist for years in
desiccation-resistant mosquito eggs.  When environmental
conditions are appropriate, these eggs hatch into infected
mosquitoes which may give rise to localised outbreaks of
infection.  This study tends to support Wolstenholme’s14
hypothesis.
There have been three genotypes or topotypes of RRV
defined, which are classified types I-III. Genotype I was
found in Queensland and north- central NSW.  This
variant has not been seen since 1976 when it was last
isolated in Charleville (QLD).  Genotype II predominates
in the eastern states of Australia and co-inhabits the north
of Australia with Genotype III.  All isolates from the south
Pacific belong to this category, and it is believed that type
II has replaced type I strains.  Genotype III is predominantly
found in Western Australia though also extends across the
north of Australia.  Occasionally type II variants are
isolated in the south-west region of Western Australia.
These incursions however, are probably due to travel of
infected humans or beasts, as opposed to this stain taking
hold in the region.2,8
CLINICAL MANIFESTATIONS
Symptoms of RRV and BFV diseases are similar, though
vary greatly from person to person.  By far the most
common symptoms noted are arthralgia/ arthritis, (usually
of acute onset), myalgia, fever, fatigue, rash and headache.
Other symptoms that may occur are, swollen lymph nodes,
anorexia, nausea, diarrhea, vomiting, sore eyes, sore throat
and tingling in the palms of the hands or soles of the
feet.3,13,21  The most commonly affected joints are the
wrists, knees, ankles, fingers, elbows, shoulders and jaw.3,20
The joint symptoms are thought to be due to a local cell-
mediated immune response rather than a humeral immune
response.4  Linn et al22 have also shown that macrophages
can be productively infected with RRV and were capable
of producing virus for over 50 days.  They contest that
RRV-induced arthritis may be due to persistent productive
infection of macrophages.  The rash tends to be more
common to BFV disease, while the joint symptoms tend to
be more severe and last longer with RRV disease.3,4  The
classic presentation in over 80% of patients with EPA, is
with a rash and joint symptoms.20
Infection can occur at any age, however clinical infection
is most commonly observed in the 20 to 50 age group.
Within this age group, the highest incidence is observed in
the 30 to 40 age group, and generally with equal numbers
of males and females.4  Children are often subclinically
infected, though when symptoms are apparent they are
generally milder and last for a shorter period of time.3,13
The duration of symptoms is different for each person,
although it appears that at least half will still be
intermittently symptomatic after six months, and at least a
quarter after twelve months.  Up to 10% will have residual
symptoms even after two years.  Some adults however will
recover within 2-6 weeks after the onset of symptoms, and
unfortunately it is not possible to predict how each person
will react.  The fever, nausea and rash usually disappear
very early in the disease, and its the arthralgia/arthritis and
muscle pain that persists.  Permanent joint damage does
not appear to be a feature of either disease.  Post-infection
immunity is conferred to most people, however there has
been a few rare cases of re-infection.  Additionally, RRV
infection does not confer immunity from BFV and vice
versa.3,13
The smallest estimate of the incubation period with RRV
disease is 7-9 days,23 but can range from 3-21 days.  The
incubation period for BFV disease is considered to be the
same as for RRV disease.13
DIAGNOSIS, DIFFERENTIALS, TREATMENT
AND PREVENTION
Diagnosis of RRV disease or BFV disease can be made by
recognising the symptoms, especially during an epidemic,
however laboratory confirmation should be sought.  Paired
sera should be obtained, and a rising antibody titre is
positive for infection.20  Haemagglutination inhibition and
several immunoassays are widely used to measure
antibodies to both viruses.  A significant level of rheumatoid
factor can interfere with some immunoassays, however
more definitive testing can overcome this problem.21
Differential diagnoses include rubella, hepatitis B, mumps,
pyogenic infections and the rheumatoid group of diseases,
for all can have similar presentations to alphavirus infection.
confirmation needs to be sought for management and
prognosis can differ greatly.20,21
Treatment is aimed at symptomatic relief using analgesics
like aspirin and paracetamol, or other non-steroidal anti-
inflammatory drugs.  Bed rest and gentle exercises are
very important and the patient also needs to guard against
depression.  One needs to keep in mind that they will
eventually get better.3,20
The only way to contract either disease is to be bitten by
an infected mosquito, so prevention relies on minimising
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the risk of mosquito bites.  The use of repellents, especially
those containing 5 to 20% DEET are effective, as is
wearing long loose clothing.  Times when mosquitoes are
most active are around dusk and dawn, so one can minimise
outdoor activities at these times.  Control of backyard
mosquito breeding grounds (Anywhere water can be
stagnant, eg roof gutters, animal drinking containers etc)
is important, and is something simple and safe the resident
can do.  Some local governments also conduct mosquito
control programmes.  At present there are no vaccines to
prevent either disease.3
Of interest, several unidentified arboviruses that cause
EPA-like disease may also be present in Australia.  A
number of patients with clinically diagnosed EPA during
a RRV outbreak proved negative in laboratory tests for all
known arboviruses.4
CONCLUSION
The clinical signs and symptoms of RRV and BFV may
often be confused with other local or systemic conditions
producing joint and muscle pain.  With the increasing
prevalence of RRV and BFV it is essential for primary
healthcare practitioners, concerned with the diagnosis and
treatment musculoskeletal pain, to at least possess a basic
understanding of the epidemiology, pathophysiology and
clinical signs and symptoms associated with these
diseases.
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